Over 12 months since this was announced to the world.......what's happened ??27 Feb 2024 07:51
Incredible that OBD appear to have ruined and lost this ground breaking opportunity............
6 Feb 2023 07:00
RNS Number : 9335O
Oxford BioDynamics PLC
06 February 2023
Oxford Biodynamics' Prostate Screening EpiSwitch® blood test significantly enhances overall detection accuracy for at risk men
· Prostate Screening EpiSwitch (PSE) blood test shows significant potential as an accurate and rapid cancer screening diagnostic
· High accuracy (94%), PPV (92%), and NPV (94%) reported in the high-impact, peer-reviewed journal Cancers
· Experts from Oxford Biodynamics, Imperial College London, University of East Anglia, and Imperial College NHS Trust contributed to multi-institutional clinical study
· This published data packet supports commercialization of the EpiSwitch® platform which includes this novel and accurate prostate cancer test
Oxford, UK - 6 February, 2023 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD's technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement.